McDonald L M, Moran P M, Vythelingum G N, Joseph M H, Stephenson J D, Gray J A
Department of Psychology, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK.
Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. doi: 10.1007/s00213-002-1173-4. Epub 2002 Aug 9.
Clozapine-like atypical antipsychotic drugs, such as olanzapine, risperidone and sertindole, bind most strongly to 5-HT(2A) receptors, which may contribute to their antipsychotic effects. Antipsychotic drugs, such as clozapine and haloperidol, have been found to enhance latent inhibition (LI) in humans and rats. LI is a process of learning to ignore irrelevant stimuli that is disrupted in acute, positive-symptom schizophrenia, and can be modelled in animals.
The aim of this study was to determine the effects of two selective 5-HT(2A) receptor antagonists, SR 46,349B and ICI 169,369, on LI, as a test of their antipsychotic potential.
Doses of the 5-HT(2A) receptor antagonists that were sufficient for receptor blockade were determined in 5-HT behavioural syndrome tests. SR 46,349B and ICI 169,369 were then tested for enhancement of LI and reversal of amphetamine-induced attenuation of LI in a conditioned suppression paradigm.
SR 46,349B (0.6-2.4 mg kg(-1) i.p.) and ICI 169,369 (10-40 mg kg(-1) i.p.) antagonised 5-hydroxytryptophan (5-HTP)-induced head twitches and wet dog shakes, which are mediated by 5-HT(2A) receptors, but had no effect on mCPP-induced hypolocomotion, which is mediated by 5-HT(2C) receptors. Neither SR 46,349B (1.2 mg kg(-1) i.p.) nor ICI 169,369 (40 mg kg(-1) i.p) affected 8-hydroxy-2-(di- n-propylamino)tetralin (8-OH-DPAT)-induced forepaw treading, suggesting that they were not in vivo 5-HT(1A) receptor antagonists. SR 46,349B (2.4 mg kg(-1) i.p.) and ICI 169,369 (40 mg kg(-1) i.p.) enhanced LI when given at both the pre-exposure and conditioning stages of the paradigm, but not when given at either pre-exposure or conditioning only. Both drugs also reversed the disruption of LI induced by D-amphetamine (1 mg kg(-1) i.p.).
The profile of SR 46,349B and ICI 169,369 in LI differs from that of clozapine and haloperidol in LI, which both enhance LI when given only at the conditioning stage of the paradigm.
氯氮平样非典型抗精神病药物,如奥氮平、利培酮和舍吲哚,与5-羟色胺(2A)受体结合最为紧密,这可能有助于其抗精神病作用。已发现抗精神病药物,如氯氮平和氟哌啶醇,可增强人类和大鼠的潜伏抑制(LI)。LI是一种学会忽略无关刺激的过程,在急性阳性症状精神分裂症中会受到干扰,并且可以在动物身上模拟。
本研究的目的是确定两种选择性5-羟色胺(2A)受体拮抗剂SR 46,349B和ICI 169,369对LI的影响,以此作为对其抗精神病潜力的测试。
在5-羟色胺行为综合征测试中确定足以实现受体阻断的5-羟色胺(2A)受体拮抗剂剂量。然后在条件性抑制范式中测试SR 46,349B和ICI 169,369对LI的增强作用以及对苯丙胺诱导的LI衰减的逆转作用。
SR 46,349B(腹腔注射0.6 - 2.4毫克/千克)和ICI 169,369(腹腔注射10 - 40毫克/千克)可拮抗由5-羟色胺(2A)受体介导的5-羟色氨酸(5-HTP)诱导的头部抽搐和湿狗样抖动,但对由5-羟色胺(2C)受体介导的mCPP诱导的运动减少没有影响。SR 46,349B(腹腔注射1.2毫克/千克)和ICI 169,369(腹腔注射40毫克/千克)均不影响8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)诱导的前爪踩踏,表明它们不是体内5-羟色胺(1A)受体拮抗剂。SR 46,349B(腹腔注射2.4毫克/千克)和ICI 169,369(腹腔注射40毫克/千克)在范式的预暴露和条件化阶段给药时均可增强LI,但仅在预暴露或条件化阶段单独给药时则无此作用。两种药物还可逆转由D-苯丙胺(腹腔注射1毫克/千克)诱导的LI破坏。
SR 46,349B和ICI 169,369在LI方面的表现与氯氮平和氟哌啶醇不同,后两者仅在范式的条件化阶段给药时可增强LI。